• 1
    Hansen MV, Gronberg A. Attitudes of European urologists to early prostatic carcinoma. Eur Urol 1995; 28: 196201.
  • 2
    Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 2428.
  • 3
    Albertsen PC, Fryback DG, Storer BE et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 62631.
  • 4
    Johansson JE, Adami HO, Andersson SO et al. High 10 year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 21916.
  • 5
    Fleming C, Wasson JH, Albertsen PC et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate patient outcomes research teams. JAMA 1993; 269: 26508.
  • 6
    Garnick MB, Fair WR. Prostate cancer. Emerging concepts. Part I. Ann Intern Med 1996; 125: 11825.
  • 7
    Klein EA. Hormone therapy for prostate cancer: a topic perspective. Urology 1996; 47 (Suppl. 1): 312.
  • 8
    Catalona WJ, Stein AJ. Staging errors in clinically localized prostatic cancer. J Urol 1982; 127: 4525.
  • 9
    Zincke H, Blute ML, Fallen MJ, Farrow GM. Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J Urol 1991; 146: 10538.
  • 10
    Partin AW, Carter HB, Chan DW et al. Prostate specific antigen in the staging of localized prostate cancer, influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 74752.
  • 11
    Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen values to predict pathologic stage an DNA ploidy. Urology 1993; 41: 20716.
  • 12
    Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Sem Surg Oncol 1994; 10: 6072.
  • 13
    Wilt TJ, Brawer MK. The prostate cancer intervention vs. observation trial, a randomized trial comparing radical prostatectomy vs. expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152: 191014.
  • 14
    Middleton RG, Thompson IM, Austenfeld MS et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol 1995; 154: 21448.
  • 15
    Lerner SE, Jacobsen SJ, Lilja H et al. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology 1996; 48: 2408.
  • 16
    Zincke H, Oesterling JE, Blute ML et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 18507.
  • 17
    Gerber GS, Thisted RA, Scardino PT et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276: 61519.
  • 18
    Ohori M, Wheeler TM, Kattan MW et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995; 154: 181824.
  • 19
    Walsh PC, Partin AW, Esptein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy. Results at 10 years. J Urol 1994; 152: 18316.
  • 20
    Paulson DP. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994; 152: 182630.
  • 21
    Blackwell KL, Bostwick DG, Myers RP et al. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage. The influence of prostate specific antigen density. J Urol 1994; 151: 156570.
  • 22
    Ravery V, Boccon-Gibod LA, Meulemans A et al. Predictive value of pathological features for progression after radical prostatectomy. Eur Urol 1994; 26: 197.
  • 23
    Whitmore WF. Jr Consensus development conference on the management of clinically localized prostate cancer. Overview: historical and contemporary. NCI Monogr 1988: 711.
  • 24
    Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for stage A adenocarcinoma: long-term results. J Urol 1990; 144: 11804.
  • 25
    Cheng WS, Frydenberg M, Bergstralh EJ et al. Radical prostatectomy for pathological stage C prostate cancer, influence of pathologic variables and adjuvant treatment on disease outcome. Urology 1993; 42: 28391.
  • 26
    Partin AW, Pound CR, Clemens J et al. Serum PSA following anatomical radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20: 71325.
  • 27
    Ohori M, Goad JR, Wheeler TM et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 18439.
  • 28
    Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 183742.
  • 29
    Schulman C. Wildschutz Th. Zlotta AR. Neoadjuvant hormonal treatment prior to radical prostatectomy. Facts and open questions. Eur Urol 1997, in press.
  • 30
    Trachtenberg J. Neoadjuvant androgen ablation therapy prior to radical prostatectomy. Quantum leap or hope unrealized? Curr Opin Urol 1996; 6: 2547.